Toggle navigation
Home
Search
Services
Blog
Contact
About
Preclinical Efficacy and Intermediate Endpoints Assays
Search grants from
Share this grant:
:
:
Abstract
Funding
Related projects
Comments
Recent in Grantomics:
Massachusetts Institute of Technology
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Women's Offender Reentry Program
Improve State &Local Health Information &Data Systems
Centers of Excellence
Grants for Faculty Development in Family Medicine
Post-Baccalaureate Faculty Fellowship
Recently added grants:
Project 2: EGFR, ODC, and the Hypusome in H. pylori-induced Gastric Cancer
Project 3: Regulation of H. pylori Virulence by Dietary Factors That Impact Gastric Cancer
Core C: Administrative Core
The effects of PD-1 on tumor-mediated ?emergency? myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN53301-4-0-2
Application #
7587159
Study Section
Project Start
2005-08-30
Project End
2009-08-29
Budget Start
Budget End
Support Year
Fiscal Year
2007
Total Cost
Indirect Cost
Related projects
NIH 2008
N01 CA
Preclinical Efficacy and Intermediate Endpoints Assays
/ Ohio State University
$1,487,781
NIH 2007
N01 CA
Preclinical Efficacy and Intermediate Biomarker Assays
Pereira, Michael /
$1,397,602
NIH 2007
N01 CA
Preclinical Efficacy and Intermediate Endpoints Assays
/
NIH 2007
N01 CA
Preclinical Efficacy and Intermediate Endpoints Assays
/
Comments
Be the first to comment on this grant